testosterone cypionate

The drug testosterone cypionate should be administered under the supervision of a physician.
During the first 3 months of treatment should be monitored indicators of liver function (transaminases, alkaline phosphatase and gamma-glutamyl) in serum every 4 weeks, and then every 3 months.

Controlling these parameters allows to reveal liver function abnormalities in the early stages. Also, this applies to patients in the later stages of primary biliary cirrhosis. Furthermore, so it is possible to quickly determine whether a patient is reacted with primary biliary cirrhosis to treatment.

In the application for the dissolution of cholesterol gallstones:
In order to assess progress in the treatment and early detection of signs of calcification of stones, gall bladder should be visualized (oral cholecystography) with a tour of blackouts in the “standing” and “lying on his back” (ultrasound) through 6-10 months after the study began. If the gallbladder can not be visualized on X-rays, or in cases of calcification of stones, poor contractility of the gall bladder or frequent bouts of colic, drug testosterone cypionate¬†should not be used.

In the treatment of patients with advanced primary biliary cirrhosis: Very rarely were cases of decompensated cirrhosis of the liver.
After discontinuation of therapy was observed regression of the manifestations of decompensation.

Long-term therapy with high-dose testosterone cypionate (28-30 mg / kg / day) can lead to serious side effects in patients with primary sclerosing cholangitis.

Patients with diarrhea should reduce the dosage of the drug. When persistent diarrhea should discontinue treatment.

Effects on ability to drive vehicles and management mechanisms

Effects on ability to drive vehicles have been identified mechanisms.